Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | DNTH | Common Stock | Award | $2.97K | +3K | +21.59% | $0.99* | 16.9K | May 31, 2022 | Direct | F1, F2 |
Id | Content |
---|---|
F1 | The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Magenta Therapeutics, Inc. 2019 Employee Stock Purchase Plan (the "ESPP") for the ESPP purchase period of December 1, 2021 through May 31, 2022. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d). |
F2 | In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on May 31, 2022. |
Title: Chief Legal Officer and Secretary